A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA

Warm Antibody Autoimmune Hemolytic Anemia Clinical Trial

Official title:
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Status Completed

Clinical Trial Summary

The primary objective of this study is to assess the efficacy of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (wAIHA).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Anemia
Anemia, Hemolytic
Anemia, Hemolytic, Autoimmune
Hemolysis
Warm Antibody Autoimmune Hemolytic Anemia

Clinical Trial Details

NCT number	NCT03764618
Study type	Interventional
Source	Rigel Pharmaceuticals
Contact
Status	Completed
Phase	Phase 3
Start date	April 24, 2019
Completion date	April 11, 2022

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05535933` - HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia	Phase 2/Phase 3
Enrolling by invitation	`NCT04138927` - A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia	Phase 3
Active, not recruiting	`NCT04657094` - Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia	Phase 2
Completed	`NCT02612558` - A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)	Phase 2